Literature DB >> 11391544

Identification of immunodominant hepatitis C virus (HCV)-specific cytotoxic T-cell epitopes by stimulation with endogenously synthesized HCV antigens.

S Urbani1, J Uggeri, Y Matsuura, T Miyamura, A Penna, C Boni, C Ferrari.   

Abstract

Hepatitis C virus (HCV)-specific CD8(+) cytotoxic T lymphocytes (CTL) are believed to play an important role in the pathogenesis of liver cell injury and viral clearance in HCV infection. Because HCV does not efficiently infect human cells in vitro and primary infected hepatocytes cannot be used as stimulator/target cells for CTL analysis, development of efficient systems to activate and expand CTL in vitro, reproducing antigen presentation to CTL occurring during natural infection, is mandatory to study CTL activity and to define the hierarchy of immunodominance of CTL epitopes. To achieve this goal, 5 different defective adenoviruses carrying structural and nonstructural HCV genes (core, core-E1-E2, E2, NS3-NS4A, NS3-NS5A) were used to induce the endogenous synthesis of HCV proteins in human adherent mononuclear cells in vitro and to allow their entry into the HLA class I cytosolic pathway of antigen processing. The cytolytic activity of peripheral blood lympho-mononuclear cells (PBMC) from HLA-A2(+) HCV-infected patients stimulated with recombinant adenovirus-infected cells was tested against target cells either pulsed with a panel of synthetic peptides containing the HLA-A2 binding motif or infected with recombinant vaccinia viruses carrying HCV genes. Our study defines a reproducible system to stimulate and expand HCV-specific CTL in vitro that mimics the conditions of antigen encounter in vivo. By this approach, we have identified several HLA-A2-restricted epitopes that should correspond to immunodominant HCV sequences recognized by CTL during natural infection. Therefore, these amino acid sequences represent ideal candidates for the design of therapeutic vaccines for chronic HCV infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11391544     DOI: 10.1053/jhep.2001.25091

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  11 in total

1.  Molecular characterization of a full genome Turkish hepatitis C virus 1b isolate (HCV-TR1): a predominant viral form in Turkey.

Authors:  Esra Yildiz; Asli Oztan; Funda Sar; Ergun Pinarbasi; Rengul Cetin-Atalay; Hikmet Akkiz; Mehmet Ozturk
Journal:  Virus Genes       Date:  2002-10       Impact factor: 2.332

2.  Unexpected maintenance of hepatitis C viral diversity following liver transplantation.

Authors:  Rebecca R Gray; Samantha L Strickland; Nazle M Veras; Maureen M Goodenow; Oliver G Pybus; Stanley M Lemon; Michael W Fried; David R Nelson; Marco Salemi
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

Review 3.  Cellular immune responses against hepatitis C virus: the evidence base 2002.

Authors:  S Ward; G Lauer; R Isba; B Walker; P Klenerman
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

4.  Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities.

Authors:  Georg M Lauer; Kei Ouchi; Raymond T Chung; Tam N Nguyen; Cheryl L Day; Deborah R Purkis; Markus Reiser; Arthur Y Kim; Michaela Lucas; Paul Klenerman; Bruce D Walker
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

5.  Adjuvant activities of novel cytokines, interleukin-23 (IL-23) and IL-27, for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A*0201 transgenic mice.

Authors:  Masanori Matsui; Osamu Moriya; Maria Laura Belladonna; Sadahiro Kamiya; François A Lemonnier; Takayuki Yoshimoto; Toshitaka Akatsuka
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

6.  DCs pulsed with novel HLA-A2-restricted CTL epitopes against hepatitis C virus induced a broadly reactive anti-HCV-specific T lymphocyte response.

Authors:  Zhongsheng Guo; Henghui Zhang; Huiying Rao; Dong Jiang; Xu Cong; Bo Feng; Jianghua Wang; Lai Wei; Hongsong Chen
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240

7.  Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot"

Authors:  Florian K Bihl; Elisabetta Loggi; John V Chisholm; Hannah S Hewitt; Leah M Henry; Caitlyn Linde; Todd J Suscovich; Johnson T Wong; Nicole Frahm; Pietro Andreone; Christian Brander
Journal:  J Transl Med       Date:  2005-05-11       Impact factor: 5.531

8.  Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties.

Authors:  Anangi Balasiddaiah; Haleh Davanian; Soo Aleman; Anna Pasetto; Lars Frelin; Matti Sällberg; Volker Lohmann; Sarene Koh; Antonio Bertoletti; Margaret Chen
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

9.  Heterologous T cell immunity in severe hepatitis C virus infection.

Authors:  Simona Urbani; Barbara Amadei; Paola Fisicaro; Massimo Pilli; Gabriele Missale; Antonio Bertoletti; Carlo Ferrari
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

10.  Functional differences in hepatitis C virus nonstructural (NS) 3/4A- and 5A-specific T cell responses.

Authors:  Fredrik Holmström; Margaret Chen; Anangi Balasiddaiah; Matti Sällberg; Gustaf Ahlén; Lars Frelin
Journal:  Sci Rep       Date:  2016-05-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.